Ginkgo Bioworks Holdings, Inc.

Listed Company

DNACIK 0001830214NYSEAcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$170.16M

Net Income

$-312.76M

Total Assets

$1.12B

Equity

$508.59M

Shares Out

61.66M

Op. Cash Flow

$-171.06M

DNA$7.89−19.29% · past yearDBEQ Basic

Daily closing prices

Business

Ginkgo Bioworks Holdings, Inc. is a synthetic biology platform company that provides cell engineering research and development services, tools, and biosecurity solutions to government and commercial customers. The company offers cell engineering solutions and tools—including automation systems, data generation services, and AI models—to enable customers in pharmaceuticals, agriculture, and industrial biotechnology to discover and optimize biological products. Ginkgo also operates a biosecurity business providing genomic surveillance and threat-monitoring platforms (Canopy and Horizon) to government customers. Revenue is generated through service fees for R&D work, downstream value sharing (royalties and milestones), and sales of automation hardware and support services.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	170	227	251	478	314
Research and development	244	424	581	1,053	1,150
General and administrative	183	246	385	1,430	863
Impairment of lease assets	0	0	96	0	0
Goodwill impairment	0	48	0	0	—
Restructuring charges	11	24	0	0	—
Total operating expenses	485	787	1,116	2,687	2,142
Loss from operations	−315	−560	−864	−2,209	−1,828
Interest income	23	39	57	20	837,000
Interest expense	0	−94,000	−93,000	−106,000	—
Loss on equity method investments	0	0	−3	−44	−77
Loss on investments	−16	−29	−55	−53	−12
Loss on deconsolidation of subsidiaries	0	−7	−43	32	0
Change in fair value of warrant liabilities	0	6	5	125	59
Other (expense) income, net	−5	4	9	8	−2
Total other income (expense)	2	12	−29	88	−10
Loss before income taxes	−314	−548	−893	−2,121	−1,838
Income tax benefit	−837,000	−479,000	−71,000	−15	−1
Net loss	−313	−547	−893	−2,105	−1,830
Basic (in dollars per share)	−5.64	−10.54	−18.37	−50.15	−1.35
Diluted (in dollars per share)	−5.64	−10.54	−18.37	−50.2	−1.39
Basic (in shares)	55	52	49	42	1,360
Weighted average common shares outstanding, diluted (in shares)	55	52	49	42	1,360
Foreign currency translation adjustment	4	−5	4	−917,000	−2
Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary	0	1	0	0	—
Unrealized gain on available-for-sale securities	−126,000	0	0	—	—
Total other comprehensive income (loss)	4	−3	4	—	—
Comprehensive loss	−309	−550	−889	−2,107	−1,838

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	167	562	944	1,316	1,550
Marketable securities	255	0	—	—	—
Accounts receivable, net	24	22	17	81	132
Accounts receivable - related parties	229,000	586,000	742,000	2	—
Prepaid expenses and other current assets	25	19	40	52	34
Total current assets	472	603	1,002	1,450	1,723
Property, plant and equipment, net	168	204	188	315	146
Operating lease right-of-use assets	361	394	207	401	148
Investments	15	49	79	112	—
Intangible assets, net	57	73	83	111	22
Other non-current assets	47	55	58	89	44
Total assets	1,120	1,377	1,665	2,539	2,071
Accounts payable	11	14	9	10	8
Deferred revenue (includes $98 and $795 from related parties)	19	28	44	48	—
Accrued expenses and other current liabilities	66	65	110	115	93
Total current liabilities	96	107	164	173	135
Deferred revenue, net of current portion (includes $64,787 and $72,260 from related parties)	75	99	158	175	—
Operating lease liabilities, non-current	417	439	222	413	0
Other non-current liabilities	23	17	24	31	36
Total liabilities	611	661	568	803	504
Commitments and contingencies (Note 12)	—	—	—	—	—
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued	0	0	0	0	0
Common stock, $0.0001 par value (Note 13)	6,000	5,000	5,000	190,000	161,000
Additional paid-in capital	6,657	6,555	6,386	6,136	3,805
Accumulated deficit	−6,150	−5,838	−5,291	−4,398	−2,298
Accumulated other comprehensive income (loss)	2	−2	1	−3	−2
Total stockholders equity	509	716	1,097	1,736	1,505
Total liabilities and stockholders equity	1,120	1,377	1,665	2,539	2,071

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−313	−547	−893	—	—
Depreciation and amortization	59	63	71	43	29
Stock-based compensation	82	112	230	1,931	1,606
Restructuring related impairment charges	0	5	0	0	—
Non-cash customer consideration	0	−1	−1	−34	−24
Change in fair value of notes receivable	6	2	2	−4	4
Change in fair value of contingent consideration liability	−4	3	9	−1	293,000
Impairment of long-lived assets	0	6	121	0	0
Deferred income tax benefit	−1	−936,000	−801,000	−15	0
Loss on disposal of equipment	0	844,000	842,000	3	0
Non-cash lease expense	30	28	28	19	—
Non-cash in-process research and development	0	20	9	1	0
Accretion of discount on marketable securities	−3	0	0	—	—
Other non-cash activity	2	1	3	2	23,000
Accounts receivable ($357, $156 and $816 from related parties)	−1	−5	50	55	−114
Prepaid expenses and other current assets	−5	10	10	−9	−4
Operating lease right-of-use assets	4	23	9	13	0
Other non-current assets	296,000	−1	3	921,000	−539,000
Accounts payable	−3	5	−1	−11	−2
Accrued expenses and other current liabilities	10	−40	17	−40	45
Deferred revenue, current and non-current ($(8,147), $(51,422) and $(17,018) from related parties)	−32	−69	−36	−36	−10
Operating lease liabilities, current and non-current	−28	−15	−23	−11	—
Other non-current liabilities	11	2	452,000	31,000	19
Net cash used in operating activities	−171	−320	−296	−252	−254
Purchases of marketable debt securities	−419	0	0	—	—
Maturities of marketable debt securities	159	0	0	—	—
Proceeds from sale of marketable debt securities	26	0	0	—	—
Purchases of property and equipment	−8	−63	−41	−52	−57
Deconsolidation of subsidiaries - cash	0	0	−43	−56	0
Business acquisitions, net of cash acquired	0	−5	0	82	−12
Purchases of notes receivable	0	0	−350,000	−40	0
Proceeds from sales of marketable equity securities	0	5	0	0	—
Proceeds from sale of equipment	574,000	648,000	4	0	0
Other	50,000	538,000	−990,000	−439,000	0
Net cash used in investing activities	−240	−62	−81	−67	−73
Proceeds from ATM offering	19	0	0	—	—
Payment of issuance costs related to ATM offering	−1	0	0	—	—
Proceeds from exercise of stock options	0	84,000	93,000	240,000	167,000
Taxes paid related to net share settlement of equity awards	0	0	−23,000	—	—
Principal payments on finance leases	−354,000	−897,000	−1	−1	−1
Contingent consideration payment	0	−922,000	−1	−521,000	0
Payment of equity issuance costs and other	0	−4,000	−580,000	—	—
Net cash provided by (used in) financing activities	18	−2	−3	95	1,534
Effect of foreign exchange rates on cash and cash equivalents	201,000	−281,000	−588,000	908,000	−19,000
Net decrease in cash, cash equivalents and restricted cash	−393	−384	−380	−223	1,207

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Ginkgo Bioworks Holdings, Inc.'s CIK number?

Ginkgo Bioworks Holdings, Inc.'s SEC CIK number is 0001830214 (1830214). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Ginkgo Bioworks Holdings, Inc.'s SEC filings?

All of Ginkgo Bioworks Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Ginkgo Bioworks Holdings, Inc. last report earnings?

Ginkgo Bioworks Holdings, Inc. (DNA) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-032093). This is Ginkgo Bioworks Holdings, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Ginkgo Bioworks Holdings, Inc.'s most recent earnings 8-K?

Ginkgo Bioworks Holdings, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-032093. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Ginkgo Bioworks Holdings, Inc.'s latest earnings 8-K →
Look up any company's CIK number →